Yinggang Xu

发表

Can axillary surgery be omitted in patients with breast pathologic complete response after neoadjuvant systemic therapy for breast cancer? A real-world retrospective study in China

Lu Xu, X. Zha, Jue Wang, 2021, Journal of Cancer Research and Clinical Oncology.

A novel nomogram containing efficacy indicators to predict axillary pathologic complete response after neoadjuvant systemic therapy in breast cancer

Xinyu Wan, X. Zha, Wenjie Shi, 2022, Frontiers in Endocrinology.

The transcribed ultraconserved element uc.51 promotes the proliferation and metastasis of breast cancer by stabilizing NONO

Jue Wang, Xiaofeng Huang, Rui Chen, 2021, Clinical & Experimental Metastasis.

Volume change rate before and after neoadjuvant systemic therapy of breast cancer is an efficacious evaluation index to predict pathological complete response

Xinyu Wan, Wenjie Shi, Lu Xu, 2023, Frontiers in Oncology.

Comparison of clinicopathological characteristics and response to neoadjuvant systemic therapy in patients with HER2-low-positive and HER2-zero breast cancer

Xinyu Wan, Wenjie Shi, Lu Xu, 2023, Journal of investigative medicine : the official publication of the American Federation for Clinical Research.

Nanoparticle albumin-bound paclitaxel-based neoadjuvant regimen: A promising treatment option for HER2-low-positive breast cancer.

Ye Wang, Xinyu Wan, Lexin Wang, 2023, Nanomedicine : nanotechnology, biology, and medicine.

Prognostic analysis of three forms of Ki‐67 in patients with breast cancer with non‐pathological complete response before and after neoadjuvant systemic treatment

Xinyu Wan, Wenjie Shi, Jue Wang, 2023, Cancer medicine.

A prospective, randomized clinical trial of emergency treatment of chemotherapy‐induced neutropenia and febrile neutropenia by pegylated recombinant human granulocyte colony‐stimulating factor (PEG‐rhG‐CSF)

X. Zha, Jue Wang, Lu Xu, 2022, British journal of clinical pharmacology.

Nomogram for predicting overall survival in patients with triple-negative apocrine breast cancer: Surveillance, epidemiology, and end results-based analysis

Xinyu Wan, X. Zha, Wenjie Shi, 2022, Breast.

Retrospective comparisons of nanoparticle albumin-bound paclitaxel and docetaxel neoadjuvant regimens for breast cancer.

Lu Xu, X. Zha, Jue Wang, 2021, Nanomedicine.

Nanoparticle albumin-bound paclitaxel is superior to liposomal paclitaxel in the neoadjuvant treatment of breast cancer.

X. Zha, Cui-ying Li, Jue Wang, 2022, Nanomedicine.

Efficacy comparisons of solvent-based paclitaxel, liposomal paclitaxel, nanoparticle albumin-bound paclitaxel, and docetaxel after neoadjuvant systemic treatment in breast cancer.

Xinyu Wan, Lu Xu, Jue Wang, 2023, Nanomedicine : nanotechnology, biology, and medicine.